Difference between revisions of "MEDICATION-ATROPINE"
From NeuroRehab.wiki
(Imported from text file) |
(Imported from text file) |
||
| Line 1: | Line 1: | ||
<div>1. Parasympathetic antagonist that increases HR by blocking vagal tone.<div>2. Indications: symptomatic bradycardia with haemodynamic compromise. A bradycardic patient with no pulse should be treated as for PEA.</div><div>3. SE: dysthymia, HTN, urinary retention, delirium, hyperthermia in large doses.</div><div><br></div><div>DOSAGE </div><div>4. Rapid boluses of 500-600 mcg every 3-5 min up to a maximum of 3 mg.</div><div>5. Do not give slowly or boluses < 500 mcg as this may irritate vagal fibres and cause a paradoxical reduction in HR.</div><div>6. Contraindicated in heart transplant patients as denervated hearts do not respond and may cause a heart block. </div> | <div>1. Parasympathetic antagonist that increases HR by blocking vagal tone.<div>2. Indications: symptomatic bradycardia with haemodynamic compromise. A bradycardic patient with no pulse should be treated as for PEA.</div><div>3. SE: dysthymia, HTN, urinary retention, delirium, hyperthermia in large doses.</div><div><br></div><div>DOSAGE </div><div>4. Rapid boluses of 500-600 mcg every 3-5 min up to a maximum of 3 mg.</div><div>5. Do not give slowly or boluses < 500 mcg as this may irritate vagal fibres and cause a paradoxical reduction in HR.</div><div>6. Contraindicated in heart transplant patients as denervated hearts do not respond and may cause a heart block. </div> | ||
==Reference(s)== | |||
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. | |||
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons. | |||
[[Category:Medication]] | [[Category:Medication]] | ||
[[Category:Advanced Life Support]] | [[Category:Advanced Life Support]] | ||
Revision as of 01:21, 17 December 2022
1. Parasympathetic antagonist that increases HR by blocking vagal tone.
2. Indications: symptomatic bradycardia with haemodynamic compromise. A bradycardic patient with no pulse should be treated as for PEA.
3. SE: dysthymia, HTN, urinary retention, delirium, hyperthermia in large doses.
DOSAGE
4. Rapid boluses of 500-600 mcg every 3-5 min up to a maximum of 3 mg.
5. Do not give slowly or boluses < 500 mcg as this may irritate vagal fibres and cause a paradoxical reduction in HR.
6. Contraindicated in heart transplant patients as denervated hearts do not respond and may cause a heart block.
Reference(s)
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council. American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons.
